Fong Y, Sun R L, Jarnagin W, Blumgart L H
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800. doi: 10.1097/00000658-199906000-00005.
Using a large single-institution experience at a Western referral center, the authors examine partial hepatectomy as treatment of hepatocellular carcinoma and relate treatment outcomes to clinical parameters, including the etiology of underlying cirrhosis.
Four hundred and twelve patients seen between December 1991 and January 1998 were identified in a prospective database. Data about the surgical procedure, perioperative complications, and long-term outcome were examined.
One hundred twenty-six patients did not have underlying cirrhosis. Of the 286 patients with cirrhosis, 119 were the result of hepatitis B, 39 hepatitis C, 36 both B and C, 43 ethanol abuse, and the remainder other causes. Two hundred forty-three patients underwent surgical exploration, and 154 patients underwent hepatic resection. Seven (4.5%) died from the surgery. One hundred forty-three patients were treated by ablative methods. Patients with cirrhosis had smaller tumors but nevertheless had a lower resectability rate. Neither the presence of cirrhosis nor the etiology of the cirrhosis altered the perioperative morbidity or mortality rate. The greatest determinant of long-term outcome was resectability. The size of the lesion, an alpha-fetoprotein level >2000 ng/ml, and vascular invasion were also determinants of poor outcome. The presence of cirrhosis was a detrimental factor when analysis was stratified for size of tumor. The cause of cirrhosis did not influence the long-term outcome. The 5-year survival rate was 57% for patients with resected lesions <5 cm and 32% for patients with tumors >10 cm.
Partial hepatectomy is safe, effective, and potentially curative therapy for hepatocellular carcinoma. The presence of cirrhosis did not affect the surgical mortality rate but did affect the long-term survival rate. The cause of cirrhosis did not influence outcome. As treatment for small hepatocellular carcinomas, partial hepatectomy produces results similar to those of transplantation. For patients with large tumors who are poor candidates for transplantation, resection results in long-term survival in one third of patients.
作者利用一家西方转诊中心的大量单机构经验,研究部分肝切除术作为肝细胞癌的治疗方法,并将治疗结果与临床参数相关联,包括潜在肝硬化的病因。
在一个前瞻性数据库中识别出1991年12月至1998年1月期间就诊的412例患者。检查了有关手术过程、围手术期并发症和长期结果的数据。
126例患者没有潜在的肝硬化。在286例肝硬化患者中,119例由乙型肝炎引起,39例由丙型肝炎引起,36例由乙型和丙型肝炎共同引起,43例由酒精滥用引起,其余由其他原因引起。243例患者接受了手术探查,154例患者接受了肝切除术。7例(4.5%)死于手术。143例患者采用消融方法治疗。肝硬化患者的肿瘤较小,但切除率较低。肝硬化的存在与否以及肝硬化的病因均未改变围手术期发病率或死亡率。长期结果的最大决定因素是可切除性。病变大小、甲胎蛋白水平>2000 ng/ml和血管侵犯也是预后不良的决定因素。当按肿瘤大小分层分析时,肝硬化的存在是一个不利因素。肝硬化的病因不影响长期结果。切除病变<5 cm的患者5年生存率为57%,肿瘤>10 cm的患者5年生存率为32%。
部分肝切除术是治疗肝细胞癌的安全、有效且可能治愈的疗法。肝硬化的存在不影响手术死亡率,但影响长期生存率。肝硬化的病因不影响预后。作为小肝细胞癌的治疗方法,部分肝切除术产生的结果与移植相似。对于那些不适合移植的大肿瘤患者,切除术后三分之一的患者可长期存活。